FAQ: What Pharmacists Should Know About 340B Program

The 340B Drug Pricing Program serves as a vital care infrastructure tool designed to help safety net providers stretch limited resources to reach more patients and provide comprehensive care.

By allowing eligible organizations to purchase outpatient drugs at significantly lower acquisition costs, the program provides a financial mechanism to support services that are often difficult to fund through traditional reimbursement models.

Ron Lanton III, Esq, partner at Lanton Law PLLC, recently joined Drug Topics to tap into his expertise in working with the 340B drug pricing program. From legislative and compliance pressures to the general crux of why the program was established in the first place, Lanton lays out exactly why programs and initiatives like these have stood the test of time in yielding improved patient outcomes despite all of the hurdles and challenges involved.

What is the fundamental purpose of the 340B Drug Pricing Program?

The fundamental purpose of 340B is pretty straightforward. It is meant to help safetynet providers stretch limited resources so they can reach more patients and provide more comprehensive care. That sounds simple, but in practice, it is one of the most important access tools we have in the outpatient pharmacy and provider setting.

I believe that 340B is more like a care infrastructure program. When a covered entity can purchase covered outpatient drugs at a lower acquisition cost, those savings can support the services that are often hardest to fund through traditional reimbursement.

That can mean medication access programs, pharmacy staff, patient counseling, care coordination, transportation support, chronic disease programs, or simply keeping a clinic viable in a community that does not have many other options.

The bottom line is that 340B works best when the savings are connected back to patient care. The program gives eligible organizations a financial tool, but the real value is what that tool allows them to do for patients who would otherwise have fewer options.

READ MORE: Drug Price Rebates and 340B Changes Impact Pharmacy Manufacturers | Asembia AXS26

What is a “covered entity” and what makes a patient eligible?

A covered entity is an eligible organization that has qualified to participate in 340B and is registered in the federal 340B database. These entities generally include certain safety net hospitals, federally qualified health centers, Ryan White clinics, hemophilia treatment centers, and other providers that serve defined patient populations or meet specific statutory requirements.

Patient eligibility is where the analysis becomes important. A person is not a 340B patient just because they walk into a pharmacy or receive a prescription. There has to be a real relationship between the patient and the covered entity. The covered entity must maintain records of the patient’s care. The patient must receive health care services from the covered entity or from a provider working under an arrangement where responsibility for the care remains with the covered entity. And the prescription generally needs to arise from that outpatient care relationship. For many grantee-covered entities, the care also has to be consistent with the scope of the grant or program that creates 340B eligibility.

That is why documentation matters so much. Can the entity show the patient relationship, the encounter, the provider connection, the outpatient status, and the prescription trail? If the answer is yes, the program is on much stronger ground.

How do 340B savings directly impact clinical services and patient care in pharmacy practice?

Savings under 340B can be the difference between a service existing and a service disappearing. That is especially true in pharmacy practice, where the pharmacy is often the most accessible point of care for patients managing chronic conditions, complicated medications, or cost barriers.

Those savings may help support medication therapy management (MTM), adherence outreach, specialty pharmacy services, bedside delivery, transitions of care, immunization programs, diabetes support, HIV care, behavioral health medication access, or patient assistance work. In a health system or clinic, the savings may also help fund pharmacists and pharmacy technicians who spend time solving the problems patients never see on a claim form—prior authorizations, affordability issues, refill gaps, therapeutic substitutions, and coordination with prescribers.

A patient may not know that 340B helped keep a pharmacist available for counseling or helped a clinic maintain a medication access program. They may simply experience it as being able to stay on therapy, afford a drug, get a refill on time, or speak with someone who understands their medication regimen.

The strongest 340B programs are able to tell that patient care story clearly. Savings should not just sit on a spreadsheet. They should connect back to access, adherence, safety, and the services that help patients stay engaged in care.

What is the pharmacist’s specific role in managing 340B workflows?

The pharmacist’s role in 340B is much bigger than dispensing. Pharmacists are often the people who understand where the clinical, billing, and compliance workflows actually meet. That makes them central to how a 340B program functions day to day.

At the operational level, pharmacists help make sure prescriptions are tied to eligible patients, eligible sites, appropriate encounters, and the right payer rules. They work with split billing systems, third-party administrators, contract pharmacy arrangements, inventory models, Medicaid carve-in and carve-out decisions, and replenishment processes. They also help identify when something does not look right, whether that is a prescription that does not appear connected to an eligible encounter or a claim that creates duplicate discount risk.

At the clinical level, pharmacists also help translate 340B into patient value. They are counseling patients, monitoring therapy, identifying adherence barriers, and working with prescribers to keep care moving.

That combination is important. A strong 340B pharmacist is not only protecting the program from compliance risk, but the pharmacist is also helping make sure the program supports real care. In many organizations, pharmacy is where 340B becomes both operationally defensible and clinically meaningful.

What are the primary danger zones regarding 340B program compliance and auditing?

The main danger zones are usually the same ones that show up when a program’s documentation, technology, and daily practice are not aligned. Diversion is the first major risk, meaning a 340B drug is used for someone who is not an eligible patient of the covered entity. Duplicate discounts are the second, meaning a drug receives both a 340B discount and a Medicaid rebate. Those 2 issues sit at the center of almost every serious 340B compliance conversation.

There are other risk areas as well. Covered entities need accurate and current records in the 340B database. They need to understand Medicaid billing status and make sure the Medicaid Exclusion File is accurate. They need policies that reflect what the organization actually does, not what someone copied from a template years ago. Contract pharmacy arrangements, referral prescriptions, telehealth encounters, mixed use inventory, GPO prohibition rules for certain hospitals, and accumulations and replenishment logic all need close attention.

The audit lesson is simple: Good intent is not enough. If the records do not support the transaction, the organization has a problem. A healthy 340B program should be self-auditing, testing claims, reviewing exceptions, updating policies, and training staff before an auditor asks the questions.

The bottom line is that 340B compliance has to be lived in the workflow; it cannot sit in a binder.

What are the most significant threats currently facing the 340B landscape?

The biggest threat to 340B right now is uncertainty. The program is being pressured from several directions at once, and that creates real challenges for providers and pharmacies trying to plan responsibly.

Manufacturer restrictions on contract pharmacy access remain one of the most visible issues. For many covered entities, contract pharmacies are not a convenience. They are how patients access medications in communities where the covered entity may not operate its own pharmacy. At the same time, manufacturers continue to push for more claims level data, more transparency, and in some cases, new models for how 340B discounts are delivered. Covered entities are trying to protect patient access while also navigating legitimate questions about program integrity and data use.

Litigation is another major pressure point. Courts, federal agencies, manufacturers, states, PBMs, and covered entities are all shaping the program in real time. Patient definition disputes, state contract pharmacy laws, anti-discrimination bills, rebate model proposals, and payer behavior all matter because they affect how 340B works in practice.

There is also a political threat. If policymakers believe the program is not clearly tied to patient benefit, the program becomes easier to attack. That means covered entities need to be able to explain how savings support services, access, and pharmacy care.

The future of 340B will likely depend on whether stakeholders can protect the program’s safety net purpose while improving transparency and accountability. That balance is where the real policy fight is heading.

Conclusion

The true value of the 340B program is realized when savings are explicitly connected back to enhanced patient care and improved access. For a program to be both operationally defensible and clinically meaningful, compliance must be “lived in the workflow,” as Lanton states, through rigorous documentation and proactive self-auditing, rather than merely existing as a set of policies.

As the 340B landscape continues to face significant pressure from manufacturer restrictions and legal challenges, the program’s longevity will likely depend on the ability of stakeholders to improve transparency and accountability while fiercely protecting its original safety net purpose. By staying central to these workflows, pharmacists ensure that 340B remains a powerful tool for bridging the gap between pharmacy savings and high-quality patient outcomes.

READ MORE: What TrumpRx Means for Independent Pharmacies and Their Patients